United Food & Commercial Workers Local 1776 v. Takeda America Holdings, Inc., 848 F.3d 89

Takeda listed three patents in connection with ACTOS; the ’777 patent (covering pioglitazone) expired Jan 17, 2011; the ’584 and ’404 patents (claiming combinations and methods) expired June 19, 2016. Plaintiffs allege Takeda falsely described the ’584 and ’404 patents to the FDA as drug-product patents.
Brand patent listings feed the Orange Book; generics use those listings when choosing between Paragraph IV certifications (challenge patents; triggers 180‑day exclusivity for first filers) and Section viii statements (carve out patented uses; no 180‑day bottleneck).
Three generics filed ANDAs on the same day with Paragraph IV certifications (first‑filers) and later shared the 180‑day exclusivity; six more later filed Paragraph IVs. Teva filed a Section viii ANDA.
FDA tentatively approved Teva’s ANDA (2006). After a citizen petition and Takeda’s confirmation of its patent descriptions, FDA announced in 2010 that ACTOS ANDAs lacking Paragraph IV certifications to the ’584 and ’404 patents would be ineligible for final approval—relying on Takeda’s representations.
Takeda sued and later settled with first‑filers and others; settlements delayed generic market entry until August 2012 (first‑filers/Teva as a distributor) and February 2013 (mass entry). Plaintiffs (buyers) sued alleging monopolization/attempted monopolization under state antitrust law.
District court dismissed for failure to plausibly plead causation for the delay; plaintiffs appealed.

Issue	Plaintiff's Argument	Defendant's Argument	Held
Whether plaintiffs plausibly alleged causation for delay by generics that filed Paragraph IVs	Takeda’s false patent descriptions forced generics into Paragraph IV, creating a 180‑day exclusivity bottleneck that delayed later entrants until 2012–2013	Plaintiffs fail to show generics knew of Takeda’s misdescriptions when they filed ANDAs; without such knowledge the causal chain breaks	Dismissed as to these generics: plaintiffs did not plead that generics knew of Takeda’s alleged misdescriptions when filing, so causation is implausible
Whether plaintiffs plausibly alleged causation for Teva (Section viii filer)	Takeda’s false descriptions caused FDA’s 2010 announcement (based on Takeda’s submissions), which derailed Teva’s Section viii path and delayed its market entry	Alternative causes (Teva’s settlement, other petitions, later FDA actions) make causation speculative	Reversed/vacated as to Teva: plaintiffs plausibly alleged Takeda caused Teva’s delay because FDA acted explicitly on Takeda’s representations
Whether speculative alternative causes justify dismissal at pleading stage	Plaintiffs: other possible causes are factual defenses for later stages, not grounds to dismiss now	Takeda: multiple plausible alternative causes defeat causation pleading	Court: alternative causes are appropriate defenses for summary judgment or trial; dismissal would be premature as to Teva

Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S, 566 U.S. 399 (Sup. Ct. 2012) (explains interplay of Orange Book listings, Paragraph IV, and Section viii carve‑outs)
Ashcroft v. Iqbal, 556 U.S. 662 (2009) (plausibility standard for pleadings)
Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (pleading must state a plausible claim)
Zenith Radio Corp. v. Hazeltine Research, Inc., 395 U.S. 100 (1969) (antitrust causation principles; need not rule out all alternative sources of injury at pleading)
In re Publication Paper Antitrust Litigation, 690 F.3d 51 (2d Cir. 2012) (antitrust causation and burden allocation at summary judgment)